Highly-sensitive tumour test under development:
This article was originally published in Clinica
Stem cell company Nexell Therapeutics has begun a two-year, multicentre study of a monoclonal antibody-based column for tumour cell enrichment, which forms the basis of a laboratory test for individual tumour cells. The test, which will be developed with the aid of a $535,000 grant from the US National Institutes of Health, will be used to detect breast, prostate and lung cancer metastases, said Irvine, California-based Nexell. Preclinical studies showed a sensitivity of one cell per 100 million blood cells, said the company.